China announces generic drug list to reduce pharmaceutical costs
25 June 2019 | By Victoria Rees (European Pharmaceutical Review)
Chinese government introduces initiative to enable generic drugs to enter market and reduce prices.
List view / Grid view
Roche
More effective, safe drugs drive biobetter market growth
4 June 2019 | By European Pharmaceutical Review
The global biobetters market is set to increase due to demand for higher efficacy and safer drugs.
Sales of generic oncology drugs surge
20 February 2019 | By European Pharmaceutical Review
A report has forecasted that the generic oncology drugs market could register an impressive 6 percent CAGR up to the year 2028...
Late-stage pipeline drugs could compete with only treatment for SMA
4 February 2019 | By European Pharmaceutical Review
A number of drugs currently in their late stages in the development process could see competition for nusinersen, the only current SMA treatment, rise...
‘Booming’ pharmaceutical industry in Scotland
31 October 2018 | By European Pharmaceutical Review
A report conducted by the University of Strathclyde has revealed that the pharmaceutical market in Scotland is booming with over £462m in exports...
NICE recommends access to venclyxto for adult leukaemia
6 October 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
NICE has issued a final appraisal determination recommending that venclyxto is made available to patients with chronic lymphocytic leukaemia...
Medtech sales to reach $522bn by 2022
26 September 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
EvaluateMedTech World Preview provides a range of insights into the expected performance of the medtech industry...
Kadcyla new deal means NICE positive recommendation in draft guidance
22 June 2017 | By Niamh Marriott (European Pharmaceutical Review)
A new deal on the breast cancer drug trastuzumab emtansine means that it can now be recommended for routine funding.
FDA approves Roche’s lung cancer companion diagnostic
6 June 2017 | By Niamh Marriott, Junior Editor
The FDA have approved Roche’s VENTANA ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients...
Relocating the EMA: An open letter from EFPIA and Pharma Heads of Research
16 May 2017 | By European Federation of Pharmaceutical Industries and Associations (EFPIA)
The EMA is a world class regulator, whose scientific recommendations are a vital element of the ongoing effort to provide EU citizens with quality medicines
Roche receives FDA approval for bladder cancer biomarker assay
5 May 2017 | By Niamh Marriott, Junior Editor
The FDA has approved Roche’s biomarker assay as a complementary diagnostic to provide PD-L1 status for patients with urothelial carcinoma...
FDA approves Roche’s high-volume immunoassay
4 May 2017 | By Niamh Marriott, Junior Editor
Roche’s new, dedicated high-volume testing immunoassay solution for the cobas 8000 modular analyser series, the cobas e 801 module, has received 510(k) clearance from the US Food and Drug Administration (FDA). As core laboratories continue to evolve to meet the growing workload demands in an increasingly challenging environment, the cobas…
2017 Pipelines: Drugs to watch
12 April 2017 | By Alexandra Kibble (Senior Editor - Clarivate Analytics Cortellis)
The annual Drugs to Watch report forecasts that eight new drugs will enter the market in 2017 and achieve blockbuster sales of more than $900 billion by 2021...
The top 21… wealthiest pharma companies
6 February 2017 | By Niamh Marriott (European Pharmaceutical Review)
European Pharmaceutical Review has been keeping the industry informed for 21 years and continues to bring insights into current and emerging technologies, contributions from recognised figures in the life science community and of course, the latest and most up to date news. To celebrate our success, we will be counting down…
FDA approves Roche’s assay to assess ovarian reserve
10 January 2017 | By Niamh Marriott, Digital Editor
The blood test produces standardised results for assessing ovarian reserve as compared with the use of vaginal ultrasound...
Follow: